Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 31;7(23):7258–7269. doi: 10.1182/bloodadvances.2023010546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 6. — The presence of ≥3 (of 5) unfavorable day 7 poor prognostic indicators is strongly associated with pre-BMT mortality. (A) Kaplan-Meier pre-BMT survival estimates based on markers obtained around day 7 of therapy. The addition of imputed data for missing values are shown in supplemental Figure 7 and gave a similar result. Survival analysis using individual day 7 markers is shown in supplemental Figure 9C. (B) An illustration of the early response assessment tool for patients receiving etoposide-based therapy indicating the need for a data-based, responsive-adaptive therapeutic strategy for HLH. Improvement = (difference between baseline and day 7 values)/baseline value; ∗∗∗∗P < .0001.